You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA193
  • Published:  28 July 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix A - provisional matrix of stakeholders

Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix A - provisional matrix of stakeholders Leukaemia (chronic lymphocytic, relapsed) - rituximab: Appendix A - provisional matrix of stakeholders
20 January 2014
(100.52 Kb 29 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 14 January 2014

Back to top